Immucell Corp
ICCCStock
$11.13+71.41%52W
Market Cap$101.27M
P/E—
Div yield—
Beta0.55
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)62.50%
Price vs S&P 500 (4W)13.80%
VGM Score64.38
Market Capitalization$101.27M
Earnings Surprise History
Q1 260.21est. —
Analyst Recommendations
Sep 2021
Oct 2021
Nov 2021
Dec 2021
4.14
4.14
4.14
4.14
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ICCCImmucell Corp | C | B | A | $11.13 |
| IDXXIdexx Laboratories Inc | D | B | C | $576.07 |
| LNTHLantheus Holdings, Inc | C | B | B | $105.11 |
| CLDXCelldex Therapeutics, Inc | F | F | B | $35.40 |
| NEOGNeogen Corp | C | C | B | $10.33 |
| NTLAIntellia Therapeutics, Inc | D | C | C | $11.86 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | F | $9.60 |
| QDELQuidelOrtho Corporation Common Stock | C | C | C | $18.24 |
| ACHVAchieve Life Sciences, Inc. | F | F | A | $5.96 |
| MYGNMyriad Genetics Inc | C | C | B | $6.19 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $5.32 |
About
ImmuCell Corp develops and commercializes health products for the dairy and beef cattle industries. The company operates two business segments: Scours (First Defense, a USDA-regulated product to prevent disease in newborn calves) and Mastitis (Re-Tain, an FDA-regulated treatment for subclinical mastitis in dairy cows). The Scours segment generates the majority of company revenue.